Good morning :)
Place Order
Add to Watchlist

SMS Pharmaceuticals Ltd

SMSPHARMA

SMS Pharmaceuticals Ltd

SMSPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,502 cr, stock is ranked 1,031
High RiskStock is 4.02x as volatile as Nifty
295.600.39% (+1.15)
295.600.39% (+1.15)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,502 cr, stock is ranked 1,031
High RiskStock is 4.02x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,502 cr, stock is ranked 1,031
High RiskStock is 4.02x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
43.944.670.14%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.296.550.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 8.79%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.21% to 0.19%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 4.47%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue615.01439.58465.07468.31417.06566.62525.07526.96713.73743.68
Raw Materialssubtract399.45325.03294.32307.19259.50313.27387.95299.72425.26614.42
Power & Fuel Costsubtract33.8118.2322.5721.7518.9923.3132.5835.9747.12
Employee Costsubtract38.1126.9232.8035.5939.3541.1751.0250.0856.78
Selling & Administrative Expensessubtract25.2310.239.679.8410.1819.0221.1225.2835.68
Operating & Other expensessubtract25.59-17.429.970.403.9045.27-87.4156.4627.66
Depreciation/Amortizationsubtract19.4319.1819.9019.2722.0722.2832.1532.1331.5232.21
Interest & Other Itemssubtract17.1115.8215.4811.9212.3211.1919.1621.9723.6021.80
Taxes & Other Itemssubtract15.3813.0928.5922.3119.1828.606.2812.4116.2818.30
EPS4.833.373.754.733.737.387.35-0.835.896.73
DPS0.200.200.250.250.250.300.300.300.400.30
Payout ratio0.040.060.070.050.070.040.040.070.04

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 2PDF
Feb 10PDF
Nov 13PDF
Oct 28PDF
FY 2023

Annual report

PDF

Investor Presentation

May 25PDF
Nov 14PDF
Aug 13PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 9PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
SMS Pharmaceuticals Ltd50.224.670.14%
Sun Pharmaceutical Industries Ltd45.326.470.75%
Cipla Ltd31.054.770.82%
Mankind Pharma Ltd57.2011.43

Price Comparison

Compare SMSPHARMA with any stock or ETF
Compare SMSPHARMA with any stock or ETF
SMSPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding64.67%2.55%0.00%0.52%32.26%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.67%0.60%0.59%0.17%0.17%0.52%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 4 Mutual Funds holding SMS Pharmaceuticals Ltd




Funds (Top 4)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
2.1003%0.20%0.20%107/110 (-3)
Quant Healthcare Fund - Growth - Direct Plan

Growth
0.9317%5.12%0.67%10/32 (-4)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0005%0.08%0.08%81/102 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SMSPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.14%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.36 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 22, 2021

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2021

Cash Dividend

Ex DateEx DateMar 26, 2020

Interim
Interim | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Mar 26, 2020

News & Opinions
Corporate
SMS Pharmaceuticals to convene board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

2 days agoCapital Market - Live
Corporate
SMS Pharmaceuticals to conduct AGM

SMS Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Board of SMS Pharmaceuticals approves incorporation of subsidiary company

The Board of SMS Pharmaceuticals at its meeting held on 05 August 2024 has approved to incorporate a Subsidiary Company in India as a Company for Contract Research Organization (CRO) services on Peptides. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals fixes record date for dividend

SMS Pharmaceuticals has fixed 23 September 2024 as record date for the purpose of determining the Members eligible to receive dividend for the financial year 2023-24, if approved. Powered by Capital Market - Live

3 months agoCapital Market - Live

SMS Pharmaceuticals consolidated net profit rises 76.45% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
SMS Pharmaceuticals consolidated net profit rises 76.45% in the June 2024 quarter

Net profit of SMS Pharmaceuticals rose 76.45% to Rs 16.48 crore in the quarter ended June 2024 as against Rs 9.34 crore during the previous quarter ended June 2023. Sales rose 21.51% to Rs 164.45 crore in the quarter ended June 2024 as against Rs 135.34 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales164.45135.34 22 OPM %20.3819.35 - PBDT30.2120.37 48 PBT21.8312.68 72 NP16.489.34 76 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals schedules board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Chemcon Speciality Chemicals Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Selan Explorations Technology Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

SMS Pharmaceuticals share price zooms after bagging licence to manufacture, supply oral COVID vaccines

2 years agoMoneycontrol